Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Lymphoid 1

Conditions

Breast Neoplasms 2Ventricular Dysfunction, Left 1Lymphoma, Large B-Cell, Diffuse 1Cardiotoxicity 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Nebivolol × Breast × Clear all
NCT07233499 2025-11-19

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

Ain Shams University

Phase 2 Recruiting
56 enrolled
Breast

Breast Neoplasms

NCT05728632 2023-02-23

CONTROL

Humanitas Hospital, Italy

Phase 3 Unknown
80 enrolled
BreastLymphoid

Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡